SCHEMBL2856152

SCHEMBL2856152

O=C(Cc1ccccn1)NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
MAPT P10636 3/20 0.55
GLA P06280 1/20 0.55
HTT P42858 1/20 0.55
TRPV1 Q8NER1 1/20 0.54
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54
TAOK1 Q7L7X3 1/20 0.53
P2RX7 Q99572 3/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HDAC1 Q13547 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22307422 0.90 POLB (0.68) POLBMAPTGLAHTTKMT2A
SCHEMBL10572999 0.82 POLB (0.77) POLBMAPTLMNAKMT2AMEN1
SCHEMBL13355292 0.81 MAPT (0.58) MAPTGLAHTTTRPV1LMNA
SCHEMBL13683247 0.80 TSHR (0.65) TRPV1LMNATP53P2RX7KMT2A
SCHEMBL22307413 0.80 KDM4E (0.57) POLBMAPTTRPV1P2RX7KMT2A
SCHEMBL2854488 0.80 ALDH1A1 (0.64) POLBLMNAKMT2AMEN1NPSR1
SCHEMBL2854299 0.80 POLB (0.61) POLBMAPTLMNATP53KMT2A
SCHEMBL2854477 0.78 MAPT (0.61) MAPTGLATRPV1LMNATP53
SCHEMBL18768851 0.77 KMT2A (0.68) MAPTGLAHTTLMNATP53
SCHEMBL11305715 0.76 TSHR (0.69) TRPV1LMNATP53TAOK1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 POLB 4035/4885MAPT 3590/4885GLA 4793/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 POLB 4035/4885MAPT 3590/4885GLA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.